Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Joincare Pharmaceutical Group Industry Co Debt-to-Equity Related Terms
Joincare Pharmaceutical Group Industry Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co Debt-to-Equity Chart
Joincare Pharmaceutical Group Industry Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joincare Pharmaceutical Group Industry Co Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a Debt-to-Equity of 0.25 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. This is 29% below median its historical median of 0.35. Over the past decade, Joincare Pharmaceutical Group Industry Co's Debt-to-Equity has ranged from 0.03 to 0.48. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #380 out of 812 companies in the Drug Manufacturers industry, placing it in the top 46.8%.
Is Joincare Pharmaceutical Group Industry Co's Debt-to-Equity too high?
Joincare Pharmaceutical Group Industry Co's current Debt-to-Equity of 0.25 is 29% below median its 10-year median of 0.35. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.48. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Joincare Pharmaceutical Group Industry Co's value of 0.25 is 9.1% below this industry median. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #380 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #380 out of 812 companies for Debt-to-Equity. This puts Joincare Pharmaceutical Group Industry Co in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Joincare Pharmaceutical Group Industry Co's value of 0.25 is 9.1% below this benchmark. Historically, Joincare Pharmaceutical Group Industry Co's own Debt-to-Equity has ranged from 0.03 to 0.48 over the past decade. While the company's 10-year median is 0.35 vs. the industry median of 0.28, Joincare Pharmaceutical Group Industry Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joincare Pharmaceutical Group Industry Co's current Debt-to-Equity of 0.25 is 9.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current Debt-to-Equity is 0.25, which is 29% below median its own 10-year median of 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a current Debt-to-Equity of 0.25. The stock's GF Value™ is $9.20, compared to a current price of $8.00 — trading 13% below its estimated fair value. The current Debt-to-Equity is 0.25, which is 29% below median its 10-year median of 0.35 and 9.1% below the Drug Manufacturers industry median of 0.28. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (XSWX:JCARE), the current Debt-to-Equity is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of $8.00 is trading 13% below its estimated GF Value™ of $9.20.
Key valuation signals for XSWX:JCARE:
Debt-to-Equity: 0.25 (29% below median its 10-year median of 0.35)
GF Value™: $9.20 vs. price of $8.00 (13% below fair value)
Industry Position: 9.1% below the Drug Manufacturers median (#380 of 812)
No single metric tells the full story. See the XSWX:JCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for XSWX:JCARE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JCARE has been successfully added to your 
